妇科肿瘤中「意外问题」的验证:单问题筛查促进姑息治疗整合与预立医疗照护计划
在两家三级中心的妇科肿瘤患者中,评估医生与非医生提供者对「意外问题」的预后判断效能。358例接受化疗或放疗的患者共获942次评估,24%一年内死亡;医生回答「否」者一年死亡率43%(「是」为10%),总体RR 3.76(95%CI 2.75-5.48),在所有提供者类型中均显著。
要点
- 「意外问题」单问题即可有效识别妇科肿瘤患者12个月死亡风险升高。
- 医生回答「否」者一年死亡率为43%,回答「是」者为10%,总体RR 3.76。
- 该关联在医生、高级实践提供者和护士中均显著,可用于早期姑息治疗转诊。
核心结论
- 「意外问题」是简单单问题工具,能有效识别妇科肿瘤患者12个月死亡风险升高。
- 该工具可用于识别适合早期转诊姑息治疗和启动预立医疗照护计划的患者。
研究设计与样本
- 在两家三级 care 中心,对妇科肿瘤提供者就其接受化疗或放疗的患者询问「意外问题」。
- 32名提供者(12名医生、7名高级实践提供者、13名护士)对358例患者完成942次评估。
主要发现
- 医生回答「否」的患者一年死亡率为43%,回答「是」者为10%。
- 回答「否」的12个月死亡总体RR为3.76(95%CI 2.75-5.48),在所有提供者类型中均显著。
- 在包括复发疾病和既往化疗超过2线等显著预测因素中,「意外问题」的RR最高。
关键数值与推荐
- 医生回答「否」者一年死亡率43%,回答「是」者10%。
- 回答「否」的12个月死亡总体RR 3.76(95%CI 2.75-5.48)。
临床怎么用
- 可将「意外问题」作为妇科肿瘤患者早期姑息治疗转诊和启动预立医疗照护计划的筛查工具。
- 医生、高级实践提供者和护士的回答均可用于风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The "surprise question" ("Would you be surprised if this patient died in the next year?") has been shown to be predictive of 12-month mortality in multiple populations, but has not been studied in gynecologic oncology (GO) patients. We sought to evaluate the prognostic performance of the surprise question in GO patients among physician and non-physician providers. METHODS: GO providers at two tertiary care centers were asked the surprise question about a cohort of their patients undergoing chemotherapy or radiation. Demographic and clinical information was chart abstracted. Mortality data were collected at one year; relative risk of death at one year based on response to the surprise question was then calculated. RESULTS: 32 providers (12 MDs, 7 APPs, 13 RNs) provided 942 surprise question assessments for 358 patients. Fifty-seven % had ovarian cancer and 54% had recurrent disease. Eighty-three (24%) patients died within a year. Patients whose physician answered "No" to the surprise question had a 43% one-year mortality (compared to 10% for "Yes"). Overall RR of 12-month mortality for "No" was 3.76 (95% CI 2.75-5.48); this association remained significant in all provider types. Among statistically significant predictors of 12-month mortality (including recurrent disease and >2 prior lines of chemotherapy), the surprise question had the highest RR. CONCLUSIONS: The surprise question is a simple, one question tool that effectively identifies GO patients increased risk of 12-month mortality. The surprise question could be used to identify patients for early referral to palliative care and initiation advance care planning.
引用
- Rauh LA, Sullivan MW, Camacho F, et al. Validation of the surprise question in gynecologic oncology: A one-question screen to promote palliative care integration and advance care planning. Gynecol Oncol. 2020. PMID: 32171568. doi:10.1016/j.ygyno.2020.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。